GT Biopharma Inc (GTBP)

[oxis007]

It all depends on the success or failure of the pipeline in the clinical trials. Again if OXS-1550 or
OXS-3550 are approved the company is worth over 1 billion dollars. However if both of them fail, unless the TriKE platform works for solid tumors, which is highly unlikely especially if in this case it didn't work with liquid tumors. The company is worthless. So again in terms of how much the company is worth, we have to wait for the data from the clinical trials.


December of this year will be an important time, because by this point the clinical trial using the TriKE platform for both solid and liquid tumors will have begun. Early data (in vivo) for TriKE for liquid tumors looks very promising, and if all goes as planned, could go through the clinic much faster than OXS-1550.

I think the real value in this company is in OXS-3550 which as stated above, uses the TriKE platform for liquid tumors. This is why I believe Altor Bioscience Corp partnered with Oxis for this trial.

June of next year will also be an important time for the company, this is when the phase l/ll trial ends and we see final results from OXS-1550.

Worth case: company is almost worthless

Best Case: The company is worth 2-3 billion.

Assuming there is a 100-1 reverse split in order to uplist, your cost per share would still only be $1.60 a share so you will be fine.